Repositioning Candidate Details
| Candidate ID: | R0012 |
| Source ID: | DB00128 |
| Source Type: | approved; nutraceutical |
| Compound Type: | small molecule |
| Compound Name: | Aspartic acid |
| Synonyms: | |
| Molecular Formula: | C4H7NO4 |
| SMILES: | N[C@@H](CC(O)=O)C(O)=O |
| Structure: |
|
| DrugBank Description: | One of the non-essential amino acids commonly occurring in the L-form. It is found in animals and plants, especially in sugar cane and sugar beets. It may be a neurotransmitter. |
| CAS Number: | 56-84-8 |
| Molecular Weight: | 133.1027 |
| DrugBank Indication: | There is no support for the claim that aspartates are exercise performance enhancers, i.e. ergogenic aids. |
| DrugBank Pharmacology: | L-aspartate is considered a non-essential amino acid, meaning that, under normal physiological conditions, sufficient amounts of the amino acid are synthesized in the body to meet the body's requirements. L-aspartate is formed by the transamination of the Krebs cycle intermediate oxaloacetate. The amino acid serves as a precursor for synthesis of proteins, oligopeptides, purines, pyrimidines, nucleic acids and L-arginine. L-aspartate is a glycogenic amino acid, and it can also promote energy production via its metabolism in the Krebs cycle. These latter activities were the rationale for the claim that supplemental aspartate has an anti-fatigue effect on skeletal muscle, a claim that was never confirmed. |
| DrugBank MoA: | There are also claims that L-aspartate has ergogenic effects, that it enhances performance in both prolonged exercise and short intensive exercise. It is hypothesized that L-aspartate, especially the potassium magnesium aspartate salt, spares stores of muscle glycogen and/or promotes a faster rate of glycogen resynthesis during exercise. It has also been hypothesized that L-aspartate can enhance short intensive exercise by serving as a substrate for energy production in the Krebs cycle and for stimulating the purine nucleotide cycle. |
| Targets: | NA; Calcium-binding mitochondrial carrier protein Aralar2; Aspartate aminotransferase, cytoplasmic; Aspartoacylase; Asparagine synthetase [glutamine-hydrolyzing]; Argininosuccinate synthase; Aminoacylase-1; Aspartate aminotransferase, mitochondrial; Aspartate--tRNA ligase, cytoplasmic; Calcium-binding mitochondrial carrier protein Aralar1; Aspartyl/asparaginyl beta-hydroxylase; Multifunctional protein ADE2; Adenylosuccinate synthetase isozyme 2; Excitatory amino acid transporter 3; Argininosuccinate synthetase, isoform CRA_a; Aspartate--tRNA ligase, mitochondrial; Isoaspartyl peptidase/L-asparaginase; Ribonuclease pancreatic; Lysozyme C |
| Inclusion Criteria: |
| Strategy ID | Strategy | Synonyms | Related Targets | Related Drugs |
|---|
| Target ID | Target Name | GENE | Action | Class | UniProtKB ID | Entry Name |
|---|
| Diseases ID | DO ID | Disease Name | Definition | Class | |
|---|---|---|---|---|---|
| I02 | 1184 | nephrotic syndrome | "A nephrosis characterized by marked increase in glomerular protein permeability resulting in marked elevation of urine protein levels, hypoalbuminemia, hyperlipidemia, and hypercoagulability." [url:https\://en.wikipedia.org/wiki/Nephrotic_syndrome, url:https\://www.niddk.nih.gov/health-information/kidney-disease/nephrotic-syndrome-adults] | Details |